SEC Form 4 · accession 0001140361-15-007863
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian P McKeon
Officer — Executive VP, CFO & Treasurer
Period of report
Feb 14, 2015
Accepted (ET)
Feb 18, 2015 · 6:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 14, 2015 | M | 363 | $0.00 | A | 14,562 | D | |
| Common Stock | Feb 14, 2015 | F | 117 | $159.08 | D | 14,445 | D | |
| Common Stock | Feb 17, 2015 | M | 5,000 | $29.27 | A | 19,445 | D | |
| Common StockF2 | Feb 17, 2015 | S | 2,000 | $156.4366 | D | 17,445 | D | |
| Common StockF3 | Feb 17, 2015 | S | 3,000 | $157.3627 | D | 14,445 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F4 | $159.08 | Feb 14, 2015 | A | 18,108 | A | — | Feb 13, 2025 | Common Stock | 18,108 | 18,108 | D |
| Incentive Stock Option (right to buy)F5 | $159.08 | Feb 14, 2015 | A | 628 | A | — | Feb 13, 2025 | Common Stock | 628 | 628 | D |
| Restricted Stock UnitF6 | — | Feb 14, 2015 | A | 1,572 | A | — | — | Common Stock | 1,572 | 9,027 | D |
| Restricted Stock UnitF7 | — | Feb 14, 2015 | M | 363 | D | — | — | Common Stock | 363 | 8,664 | D |
| Non-Qualified Stock Option (right to buy)F8 | $29.27 | Feb 17, 2015 | M | 5,000 | D | — | May 17, 2015 | Common Stock | 5,000 | 0 | D |
Explanation of responses
- F1The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 02/20/2014.
- F2The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $155.91 to $156.84, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
- F3The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $156.91 to $157.90, inclusive.
- F4Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that becomes exercisable as to 3,748 shares on 02/14/2016, 3,747 shares on 02/14/2017, 02/14/2018 and 02/14/2019, and the remaining 3,119 shares on 02/14/2020.
- F5Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vests on the fifth anniversary date (02/14/2020) of the grant.
- F6Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2016) of the date of grant.
- F7Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vested in five equal annual installments, beginning on the first anniversary date (02/14/2015) of the date of grant.
- F8Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested fully on 05/10/2006.